Recent Updates
Recently added Catalysts
CHRS

Coherus BioSciences to Report Second Quarter 2016 Financial Results on August 9th

Key Takeaway: REDWOOD CITY, Calif., July 25, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its second quarter 2016 financial results will be released on August 9, 2016. At 4:30 p.m. Eastern Time, Coherus’ management will host a conference call to discus

Full Press Release Details

REDWOOD CITY, Calif., July 25, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its second quarter 2016 financial results will be released on August 9, 2016. At 4:30 p.m. Eastern Time, Coherus’ management will host a conference call to discuss the results for the quarter and provide a general business update.
Financial results will be released after market close on Tuesday, August 9, 2016 and posted at http://investors.coherus.com.
Conference Call Information
When: Tuesday, August 9, 2016 at 4:30 p.m. ET
Dial-in: (844) 452-6826 (toll free) or (765) 507-2587 (International)
Conference ID: 46774291
Please join the conference call at least 10 minutes early to register. The webcast will be archived on the Coherus website.
About Coherus BioSciences, Inc.
Coherus is a leading global biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology and multiple sclerosis. For additional information, please visit www.coherus.com.

Contact Data

Senior Vice President, Investor Relations
Coherus BioSciences, Inc.

Contact

With a Reader Account, it's easy to send email directly to the contact for this release. Sign up today for your free Reader Account!
Already have an account? Log in here.
Last updated: Jul 25, 2016